newsfilter
← Earnings
Earnings Releases·

Incyte — Third Quarter 2026 Earnings Summary

Incyte reported third-quarter 2026 total revenue of $1.56 billion and total net sales of $1.32 billion, representing a 14% increase compared to the same period in 2025. Jakafi net sales rose 4% to $827 million, while the core business excluding Jakafi grew significantly with Opzelura sales reaching $255 million and Hematology and Oncology portfolio sales totaling $235 million. The company raised its full-year 2026 financial guidance for Opzelura, Hematology and Oncology, and total net sales, citing strong commercial performance and pipeline progress. Additionally, Incyte advanced multiple registrational programs, including Phase 3 studies for INCA033989 in myelofibrosis and essential thrombocythemia, and latarcibart for von Willebrand disease.

Company
INCYTE CORP
Sector
Healthcare
Industry
Biotechnology